USNA

USANA Health Sciences Inc

Add to Watchlist

Advanced Chart

31.950

-0.14(-0.436%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

32.490

Open

32.290

VWAP

32.04

Vol

175.65K

Mkt Cap

595.01M

Low

31.870

Amount

5.63M

EV/EBITDA(TTM)

6.40

Total Shares

19.05M

498.17M

EV/OCF(TTM)

P/S(TTM)

0.67

USANA Health Sciences, Inc. and subsidiaries is a global nutrition, personal health and wellness company that develops and manufactures science-based nutritional and personal care products. Its segments include Direct selling and Hiya direct-to-consumer. The Direct Selling segment develops and manufactures science-based nutritional, personal care and skincare products with a primary focus on promoting long-term health and wellness in various geographic markets worldwide that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children’s health and wellness products in the United States that are distributed through the direct-to-consumer channel. Its product line includes USANA Nutritionals Optimizers, Essentials/CellSentials, and Foods. USANA Nutritionals Optimizers products include Proflavanol, CoQuinone 30, and BiOmega-3. Essentials/CellSentials products include USANA CellSentials and HealthPak 100.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

224.13M

+11.94%

0.470

-16.07%

244.97M

+14.68%

0.680

+6.25%

281.81M

+12.93%

0.800

+9.59%

Estimates Revision

The market is revising No Change the revenue expectations for USANA Health Sciences, Inc. (USNA) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 16.01%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+16.01%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for USANA Health Sciences Inc (USNA.N) is 11.75, compared to its 5-year average forward P/E of 17.60. For a more detailed relative valuation and DCF analysis to assess USANA Health Sciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

17.60

Current PE

11.75

Overvalued PE

21.50

Undervalued PE

13.69

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

7.07

Current EV/EBITDA

4.28

Overvalued EV/EBITDA

9.43

Undervalued EV/EBITDA

4.72

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

1.24

Current PS

0.61

Overvalued PS

1.60

Undervalued PS

0.88